Penciclovir

Revision as of 16:27, 31 December 2013 by Gerald Chi (talk | contribs) (Changed protection level for "Penciclovir" ([Edit=Allow only autoconfirmed users] (expires 16:27, 14 January 2014 (UTC)) [Move=Allow only autoconfirmed users] (expires 16:27, 14 January 2014 (UTC))))
Jump to navigation Jump to search
Penciclovir
Clinical data
Pregnancy
category
Routes of
administration
Topical
ATC code
Legal status
Legal status
  • S2 (Au)
Pharmacokinetic data
Bioavailability1.5% (oral), negligible (topical)
Protein binding<20%
MetabolismViral thymidine kinase
Elimination half-life2.2–2.3 hours
ExcretionRenal
Identifiers
CAS Number
PubChem CID
DrugBank
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC10H15N5O3
Molar mass253.258 g/mol

Penciclovir (INN) (IPA: Template:IPA) is a guanine analogue antiviral drug used for the treatment of various herpesvirus infections. It is a nucleoside analogue which exhibits low toxicity and good selectivity. Because penciclovir is absorbed poorly when given orally (by mouth) it is used more as a topical treatment, and is the active ingredient in the cold sore medications Denavir and Fenistil. Famciclovir is a prodrug of penciclovir with improved oral bioavailability.

Mode of action and selectivity

Penciclovir is inactive in its initial form. Within a virally infected cell a viral thymidine kinase adds a phosphate group to the penciclovir molecule; this is the rate-limiting step in the activation of penciclovir. Cellular (human) kinases then add two more phosphate groups, producing the active penciclovir triphosphate. This activated form inhibits viral DNA polymerase, thus impairing the ability of the virus to replicate within the cell.

The selectivity of penciclovir may be attributed to two factors. Firstly, cellular thymidine kinases phosphoylate the parent form significantly less rapidly than does the viral thymidine kinase, so the active triphosphate is present at much higher concentrations in virally infected cells than in uninfected cells. Secondly, the activated drug binds to viral DNA polymerase with a much higher affinity than to human DNA polymerases. As a result penciclovir exhibits negligible cytotoxicity to healthy cells.

The structure and mode of action of penciclovir is very similar to that of other nucleoside analogues such as the more widely used aciclovir. A difference between aciclovir and penciclovir is that the active triphosphate form of penciclovir persists within the cell for a much longer time than the activated form of aciclovir, so the concentration within the cell of penciclovir will be relatively higher given equivalent cellular doses.

de:Penciclovir Template:WikiDoc Sources